Intelligence Feed event · Policy · 2026-09-09

    CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M

    Question

    CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M

    Direct answer

    CRISPR Therapeutics reported accelerating commercial adoption of its blood disorder therapy Casgevy, with second-quarter sales surging 78% quarter-over-quarter to $76 million. The commercial milestone was accompanied by U.S. FDA label expansion approval covering pediatric patients aged 2 and older, materially expanding the eligible patient population for the gene editing treatment developed in partnership with Vertex Pharmaceuticals.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-09
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M”, revision 1, evidence through 2026-09-09. https://marketontology.com/market-events/2026-09-09/crispr-therapeutics-expands-casgevy-label-to-pediatric-patients-as-q2-sales-hit-291618

    POLICY
    CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M
    CRISPR Therapeutics reported accelerating commercial adoption of its blood disorder therapy Casgevy, with second-quarter sales surging 78% quarter-over-quarter to $76 million. The commercial milestone was accompanied by U.S. FDA label expansion approval covering pediatric patients aged 2 and older, materially expanding the eligible patient population for the gene editing treatment developed in partnership with Vertex Pharmaceuticals.
    CRSPVRTX
    Impact
    72
    SEP 9
    SIG
    88%
    CRSPVRTX
    CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M
    CRISPR Therapeutics reported accelerating commercial adoption of its blood disorder therapy Casgevy, with second-quarter sales surging 78% quarter-over-quarter to $76 million. The commercial milestone was accompanied by U.S. FDA label expansion approval covering pediatric patients aged 2 and older, materially expanding the eligible patient population for the gene editing treatment developed in partnership with Vertex Pharmaceuticals.
    → Pediatric FDA label expansion increases the addressable patient population, accelerating Casgevy royalty revenue and cash flow conversion for CRISPR Therapeutics.
    Impact
    CRISPR Therapeutics reported accelerating commercial adoption of its blood disorder therapy Casgevy, with second-quarter sales surging 78% quarter-over-quarter to $76 million. The commercial milestone was accompanied by U.S. FDA label expansion approval covering pediatric patients aged 2 and older, materially expanding the eligible patient population for the gene editing treatment developed in partnership with Vertex Pharmaceuticals.
    Affected
    CRSPVRTX
    Transmission
    Pediatric FDA label expansion increases the addressable patient population, accelerating Casgevy royalty revenue and cash flow conversion for CRISPR Therapeutics.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    CRSPcommercial revenue acceleration and expanded total addressable market via pediatric FDA approvalUp1-4wCasgevy revenue increased 78% QoQ to $76M and received FDA approval for pediatric patients aged 2+.
    VRTXcommercial collaboration revenue recognition on expanded Casgevy patient baseUp1-4wVertex co-commercializes Casgevy with CRISPR Therapeutics.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    VRTXUpdisagreed521.12 2026-09-09-1.26%-1.51%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month